Antihistamines in Eosinophilic Esophagitis

• Status: Recruiting
• Trial end date: 2021-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Researchers are assessing the safety and effectiveness of antihistamines in the treatment of eosinophilic esophagitis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mayo Clinic
• Treatments: Famotidine; Histamine Antagonists; Histamine H1 Antagonists; Loratadine

Criteria

Inclusion Criteria:

• Patients over the age of 18, male and female.

• Patients who carry the diagnosis of EoE based on esophageal biopsies obtained within 6 months prior to enrollment (>15 eosinophils per hpf on at least 2 esophageal levels)

• Subjects must be able to give appropriate informed consent

Exclusion Criteria:

• Not willing or able to sign consent.

• Patients who have used topical or systemic corticosteroid therapy for any reason in the previous 6 weeks.

• Patients who have been treated with acid-suppressing medications (PPI or H2 receptor antagonists) in the previous 6 weeks.

• Patients on immunosuppressive or immunomodulating medications in the previous 6 weeks.

• Patients with known allergies or hypersensitivity to anti-histamines.

• Patients who have contraindications to the procurement of esophageal biopsies including patients who have known bleeding disorders, a history of bleeding diathesis, or who are currently using warfarin or clopidogrel.

• Patients who have a contraindication to the performance of an esophagogastroduodenoscopy (EGD) including previous cardiopulmonary arrest during an endoscopic procedure.

• Patients who are pregnant.